Article
Robustness of amplicon deep sequencing underlines its utility in clinical applications.
The Journal of molecular diagnostics : JMD - 1 Jul 2013
Grossmann Vera, Roller Andreas, Klein Hans-Ulrich, Weissmann Sandra, Kern Wolfgang, Haferlach Claudia, Dugas Martin, Haferlach Torsten, Schnittger Susanne, Kohlmann Alexander
Abstract excerpt
We investigated the robustness of amplicon deep sequencing to study its utility in routine clinical applications offering patient-specific individualized assays for molecular disease characterization and monitoring. Amplicons were designed targeting RUNX1, CEBPA, CBL, NRAS, KRAS, DNMT3A, EZH2, and TP53 using different PCR amplification strategies and Roche GS FLX Titanium and Illumina MiSeq sequencing platforms....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.